AptarGroup Sets CEO Succession as 2025 Sales Increase and Shareholder Vote Back

Important Points

• Interested in AptarGroup, Inc.? Here are five stocks we like best.

• The CEO change announced: AptarGroup CEO Stephan Tanda plans to retire on September 1, 2026, and Gael Touya, currently head of Aptar Pharma, will take over as president and CEO. Tanda will remain a consultant until the end of the year to help ensure a smooth handover.

• Shareholders approved all voting items: At the annual meeting, investors elected four directors, approved advisory executive compensation, and approved PricewaterhouseCoopers as Aptar’s auditor for 2026. No shareholder nominations or other proposals were presented.

• 2025 results and outlook were strong: Aptar reported sales growth of 5% to $3.8 billion by 2025, while Pharma leads the growth category and the company returned $486 million to shareholders through buybacks and dividends. Management said sales for the first quarter of 2026 were up a reported 11%, while long-term targets remained unchanged.

AptarGroup (NYSE:ATR) used its annual meeting to announce a planned CEO transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.

President and Chief Executive Officer Stephan Tanda has told shareholders that he plans to retire after nearly 10 years in the role. Gael Touya, currently president of Aptar Pharma and a veteran of the company for more than 30 years, will become president and CEO on September 1, 2026.

→ The Restoration of the Speed ​​of Light: Corning Cashes In on NVIDIA’s Growth

Tanda said he will continue his work until the day of transition and then work as a consultant until the end of the year to support the handover. He also said he expects to retire from the board at the end of the year, and the board expects to appoint Touya as a director on September 1, 2026.

Touya said he was “lucky” to land the role and thanked Tanda for his leadership, adding that Aptar has been his “professional home” for more than 30 years.

Shareholders Approve Directors, Compensation and Auditor

→ Uber’s Annual Product Showcase Reveals It’s Coming to Airbnb and Booking

Irene Hudson, executive vice president, chief legal officer and secretary, said a quorum was present at the virtual meeting only. He said that the company had not yet received the notice of appointment of shareholders or other proposals, leaving only the issues listed in the notice of the annual meeting to be considered.

Based on the initial vote count, shareholders elected four directors to serve until the 2029 annual meeting: George L. Fotiades, Candace Matthews, B. Craig Owens and Julie Xing. Shareholders also approved, on an advisory basis, Aptar’s executive compensation and approved PricewaterhouseCoopers LLP as an independent registered public accounting firm for 2026.

→ Wells Fargo’s Comeback Is Real—But It’s Not Risky

Tanda declared each proposal approved after the inspector of elections reported that the required votes were in favor of the nominees and other ballot items. No shareholder questions were submitted during the question-and-answer portion of the meeting, according to Mary Scafidas, senior vice president of investor relations and communications.

2025 Sales Increase by 5%

After the meeting adjourned, Tanda reviewed the company’s business performance and recent results. He said the year 2025 was inspired by Aptar’s mission to “innovate and transform ideas into solutions that improve everyday life,” pointing to technologies that deliver medicines, add convenience and safety to consumers, and support reusability, reusability and sustainability.

By 2025, reported sales are up 5% to $3.8 billion from $3.6 billion last year. Core sales were up 2%, which Tanda said reflected continued demand across key product categories. The company returned $486 million to shareholders through share repurchases and dividends during the year. Tanda also noted that 2025 marks Aptar’s 32nd consecutive year of paying increasing dividends every year.

Pharma Leads Growth Segment

Tanda highlighted the strength and diversity of the company’s Pharma pipeline, citing an increasing number of planned nasal drug delivery projects and increased participation in injectable projects, including the GLP-1 and NX-1 projects. The Pharma segment reported sales growth of 6% in 2025 to $1.74 billion, driven by strong demand for emergency medicine and central nervous system products and high revenue.

In the Beauty category, reported sales increased 7% in 2025 to $1.31 billion, with cash and acquisitions having a positive impact and core sales showing modest growth. The Closure segment reported sales growth of 2% to $730.3 million, including a capital gain and a slight increase in core sales.

Capital Allocation and Outlook for 2026

Tanda said Aptar is focused on investing in returnable and fast-growing businesses, especially Pharma, while being committed to returning capital to shareholders. Over the past five years, the company has returned $1.2 billion to shareholders through dividends and share repurchases.

For the first quarter of 2026, Tanda said reported sales increased 11%, while core sales, adjusted for currency effects and acquisitions, were lower compared to the prior year.

He also emphasized safety, employee engagement, leadership development and community involvement. Tanda said the company’s goal of breaking even remains a priority and noted the continued expansion of Aptar’s Corporate University.

Aptar’s long-term financial goals remain unchanged, including an adjusted EBITDA target of 21% to 23% and a core sales growth target of 4% to 7%. Tanda said the company intends to continue to develop a production plan aimed at addressing short-term problems and improving efficiency in all operations, supply and sales chains, general and administrative costs.

“In conclusion, 2025 has been a strong year, and we are well positioned for broad-based growth in all three of our divisions,” said Tanda. He added that Aptar’s balance sheet gives the company the ability to invest in the future, return cash to shareholders and maintain flexibility for key opportunities.

About AptarGroup (NYSE:ATR)

AptarGroup, Inc is a global provider of advanced logistics solutions, packaging and protection in the consumer and pharmaceutical markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base includes the beauty and personal care, home care, food and beverage, and pharmaceutical sectors, where innovation in packaging and drug delivery systems drives product differentiation and regulatory compliance.

In the consumer market, AptarGroup offers pumps, actuators, valves, closures and special bottles designed for precision, accuracy and sustainability.

This quick news alert is generated by the scientific narrative expertise and financial data from MarketBeat to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

The article “AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot” was originally published by MarketBeat.

View MarketBeat’s top stocks for May 2026.